Delving into the Latest Updates on Smith, Gambrell & Russell LLP with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	4
Neoplasms	3
Endocrinology and Metabolic Disease	2
Immune System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	9

Top 5 Target	Count

QPCTL(glutaminyl-peptide cyclotransferase like)	2
SLC6A19(solute carrier family 6 member 19)	1
EBP(EBP cholestenol delta-isomerase)	1
NLRP3(NACHT, LRR and PYD domains-containing protein 3)	1
DGK(Diacylglycerol kinase)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

9

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SLC6A19 inhibitors(Smith, Gambrell & Russell) ( SLC6A19 )	Phenylketonurias More	Discovery
MRGPRX2 antagonists(Smith, Gambrell & Russell) ( MRGPRX2 )	Inflammation More	Discovery
NLRP3 inhibitors(Smith, Gambrell & Russell) ( NLRP3 )	Asthma More	Discovery
EBP inhibitors(Smith, Gambrell & Russell) ( EBP )	Multiple Sclerosis More	Discovery
QPCTL inhibitors(Smith, Gambrell & Russell) ( QPCTL )	Neoplasms More	Discovery